Uji klinis Migrain di Minnesota
7 studi untuk Migrain mencari peserta di lokasi di Minnesota.
Kota di Minnesota
Teks studi resmi (Bahasa Inggris)
A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine
- Clinical Research Institute, Minneapolis
Menerima pesertaFase 1
Usia 6 hingga 11 · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT06995729Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
- Clinical Research Institute, Minneapolis
Menerima pesertaFase 3
Usia 6 hingga 17 · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT05156398Randomized Study in Children and Adolescents With Migraine: Acute Treatment
- Brackenridge Outpatient Research Pharmacy, Rochester
- Clinical Research Trials Unit, Rochester
- Mayo Clinic, Rochester
Menerima pesertaFase 3
Usia 6 hingga 17 · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT04649242Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
- Mayo Clinic, Rochester
Menerima pesertaFase 4
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT06972056Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
- Minneapolis Clinic of Neurology - Burnsville /ID# 232551, Burnsville
Menerima pesertaFase 3
Usia 6 hingga 17 · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT05125302A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
- Clinical Research Institute, Minneapolis
Menerima pesertaFase 3
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 20 Agu 2026 · NCT07645924Investigating Brain Function in People With and Without Visual Snow Syndrome Using Adaptation to Visual Stimuli
- University of Minnesota, Minneapolis
Menerima pesertaSukarelawan sehat diterima
Usia 18 hingga 60 · Semua jenis kelamin · Diperbarui 14 Jan 2026 · NCT06961864Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.